This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Benralizumab parenteral

Updated 2 Feb 2023 | Interleukin antagonist


Injection solution of benralizumab.

Drugs List

  • benralizumab pre-filled pen 30mg/1ml injection solution
  • benralizumab pre-filled syringe 30mg/1ml injection solution
  • FASENRA PRE-FILLED PEN 30mg/1ml injection solution
  • FASENRA PRE-FILLED SYRINGE 30mg/1ml injection solution
  • Therapeutic Indications


    Severe eosinophilic asthma: Add-on maintenance treatment


    Patients may self administer following appropriate training.

    Continuation of treatment should be assessed on the yearly basis taking into account the disease severity, level of exacerbation control and counts of blood eosinophils.


    30mg by subcutaneous injection every 4 weeks for the first 3 doses, followed by 30mg every 8 weeks thereafter.

    Additional Dosage Information

    In the event of a missed dose benralizumab should be administered as soon as possible following the planned dates and avoiding the double dose.


    Subcutaneous injection into the thigh or abdomen.
    The upper arm can be used if administered by a healthcare professional or a carer.


    Children under 18 years

    Precautions and Warnings

    History of anaphylaxis
    Susceptibility to helminth infections

    Not suitable for acute treatment of asthma
    Avoid abrupt withdrawal of concurrent corticosteroids
    Treat helminth infection before initiation of therapy
    Treatment to be prescribed under the supervision of a specialist
    Contains polysorbate
    Avoid injection into broken or bruised skin
    Consider temporary discontinuation if helminth infection occurs
    Discontinue if hypersensitivity reactions occur
    Advise patient to consult physician if condition worsens / does not improve

    Pregnancy and Lactation


    Use benralizumab with caution during pregnancy.

    The manufacturer advises that it is preferable to avoid benralizumab during pregnancy.

    There is an increased potential for exposure to the fetus during the second and third trimester of pregnancy.

    Animal studies do not show any maternal, embryo-foetal and postnatal effects of benralizumab administration.


    Benralizumab is contraindicated during breastfeeding.

    The manufacturer advises that the patient either discontinues benralizumab or discontinues breastfeeding.

    The presence of benralizumab in human breast milk is unknown but due to its high molecular weight it is predicted that the amount in milk is likely to be very low.

    Side Effects

    Anaphylactic reaction
    Hypersensitivity reactions
    Injection site reactions


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2021

    Reference Sources

    Summary of Product Characteristics: Fasenra 30mg solution for injection in pre-filled syringe and in pre-filled pen. AstraZeneca UK Limited. Revised January 2021.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Benralizumab Last revised: 20 July 2020
    Last accessed: 30 November 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.